Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin

Show full item record



Permalink

http://hdl.handle.net/10138/314838

Citation

Baron , F , Galimard , J-E , Labopin , M , Yakoub-Agha , I , Niittyvuopio , R , Kroeger , N , Griskevicius , L , Wu , D , Forcade , E , Richard , C , Aljurf , M , Helbig , G , Labussiere-Wallet , H , Mohty , M & Nagler , A 2020 , ' Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin ' , Haematologica , vol. 105 , no. 4 , pp. 1138-1146 . https://doi.org/10.3324/haematol.2019.227603

Title: Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
Author: Baron, Frederic; Galimard, Jacques-Emmanue; Labopin, Myriam; Yakoub-Agha, Ibrahim; Niittyvuopio, Riitta; Kroeger, Nicolaus; Griskevicius, Laimonas; Wu, Depei; Forcade, Edouard; Richard, Carlos; Aljurf, Mahmoud; Helbig, Grzegorz; Labussiere-Wallet, Helene; Mohty, Mohamad; Nagler, Arnon
Other contributor: University of Helsinki, HUS Comprehensive Cancer Center



Date: 2020-04
Language: eng
Number of pages: 9
Belongs to series: Haematologica
ISSN: 0390-6078
DOI: https://doi.org/10.3324/haematol.2019.227603
URI: http://hdl.handle.net/10138/314838
Abstract: We compared severe graft-versus-host-disease GyHD) free and relapse-free survival and other transplantation outcomes of acute myeloid leukemia (AML) patients given bone marrow (BM) without and-thymocyte globulin (ATG) versus peripheral blood stem cells (PBSC) with ATG after myeloablative conditioning. In the cohort of patients receiving grafts from a human leukocyte antigen (HLA)-matched sibling donor, patients given PBSC with ATG (n=1,021) and those given BM without ATG (n=1,633) presented comparable severe GvHD-free relapse-free survival (GRSF)(hazard ratio [HR]=0.9, 95% confidence interval [CI]: 0.8-1.1, P=0.5) and overall survival (HR=1.0, 95% CI: 0.8-1.2, P=0.8). They had however, a lower incidence of chronic GvHD (cGvHD) (HR=0.7, 95% CI: 0.6-0.9, P=0.01). In the cohort of patients receiving grafts from HLA-matched unrelated donor , patients given PBSC with ATG (n=2,318) had better severe GvHD-free and relapse-free survival (GRFS) than those given BM without ATG (n=303) (HR=0.8, 95% CI: 0.6-0.9, P=0.001). They also had a lower incidence of cGvHD (HR=0.6, 95% CI: 0.5-0.8, P=0.0006) and better overall survival (HR=0.8, 95% CI: 0.6-1.0, P=0.04). In summary, these data suggest that PBSC with ATG results in comparable (in the case of sibling donor) or significantly better (in the case of unrelated donor) severe GRFS than BM without ATG in patients with AML in complete remission receiving grafts after myeloablative conditioning.
Subject: VERSUS-HOST-DISEASE
LEUKEMIA WORKING PARTY
ACUTE MYELOID-LEUKEMIA
TERM-FOLLOW-UP
RELAPSE-FREE SURVIVAL
CHRONIC GRAFT
EUROPEAN GROUP
RANDOMIZED-TRIAL
IMPACT
OUTCOMES
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1138.full.pdf 1.979Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record